An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma (Q79431834)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17167528%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

editorial

0 references

title

An internationally recognized uniform cytogenetic classification system is needed for multiple myeloma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17167528%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17167528%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

publication date

1 January 2007

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17167528%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17167528%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

volume

21

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17167528%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

issue

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17167528%20AND%20SRC:MED&resulttype=core&format=json

23 December 2019

page(s)

9-11

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:17167528%20AND%20SRC:MED&resulttype=core&format=json

Bortezomib appears to overcome the poor prognosis conferred by chromosome 13 deletion in phase 2 and 3 trials

23 December 2019

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Prognostic and biological implications of genetic abnormalities in multiple myeloma undergoing autologous stem cell transplantation: t(4;14) is the most relevant adverse prognostic factor, whereas RB deletion as a unique abnormality is not associated

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Both chromosome 13 abnormalities by metaphase cytogenetics and deletion of 13q by interphase FISH only are prognostically relevant in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Prognostic impact of cytogenetic and interphase fluorescence in situ hybridization-defined chromosome 13 deletion in multiple myeloma: early results of total therapy II.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Relationship of patient survival and chromosome anomalies detected in metaphase and/or interphase cells at diagnosis of myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Deletion of chromosome 13 detected by conventional cytogenetics is a critical prognostic factor in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Predictive role of interphase cytogenetics for survival of patients with multiple myeloma.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Hypodiploidy is a major prognostic factor in multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Oncogenesis of multiple myeloma: 14q32 and 13q chromosomal abnormalities are not randomly distributed, but correlate with natural history, immunological features, and clinical presentation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Cytogenetic Abnormalities Correlate with the Plasma Cell Labeling Index and Extent of Bone Marrow Involvement in Myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Prognostic and therapeutic significance of myeloma genetics and gene expression profiling.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Bortezomib plus melphalan and prednisone in elderly untreated patients with multiple myeloma: results of a multicenter phase 1/2 study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Recurrent 14q32 translocations determine the prognosis of multiple myeloma, especially in patients receiving intensive chemotherapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

The t(4;14) is associated with poor prognosis in myeloma patients undergoing autologous stem cell transplant

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Poor outcome with front-line autologous transplantation in t(4;14) multiple myeloma: low complete remission rate and short duration of remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

International staging system for multiple myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Chromosome abnormalities clustering and its implications for pathogenesis and prognosis in myeloma

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

The t(4;14)(p16.3;q32) is strongly associated with chromosome 13 abnormalities in both multiple myeloma and monoclonal gammopathy of undetermined significance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

p53 gene deletion detected by fluorescence in situ hybridization is an adverse prognostic factor for patients with multiple myeloma following autologous stem cell transplantation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021

Prognostic factors for hyperdiploid-myeloma: effects of chromosome 13 deletions and IgH translocations.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.LEU.2404450

7 January 2021